Neurocrine Biosciences Inc. (NASDAQ: NBIX) has initiated a Phase 1 clinical study of NBIP-2118, an investigational obesity treatment that targets ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE